



Genomic Health, Inc.
Investor Relations Department
301 Penobscot Dr.
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: GHDX

| | |
|---------------|----------------------------------------------------|
| Last Trade: | 34.90 |
| Trade Time: | 3:36 PM ET Jan 16, 2018 |
| Change: | -0.51 ↓ (-1.427%) |
| Day Range | 34.67 - 35.73 |
| 52-Week Range | 26.37 - 37.50 |
| Volume | 69,587 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 21, 2017*
[Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)
- Dec 11, 2017*
[Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum](#)
- Dec 6, 2017*
[Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development](#)
- Nov 30, 2017*
[Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging](#)
- Nov 28, 2017*
[Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests](#)

Financials & Filings [\[View all \]](#)

- Mar 15, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)

